0000000000769053

AUTHOR

Thomas Elter

showing 2 related works from this author

Elimination of Established Risk-Factors in Primary Central Nervous System Lymphoma - Impact of High-Dose Chemotherapy Followed by Autologous Stem-Cel…

2011

Abstract Abstract 3089 Introduction: High-dose chemotherapy (HDT) and autologous stem-cell transplantation (ASCT) demonstrated high efficacy in the treatment of newly-diagnosed primary CNS lymphoma (PCNSL) in eligible patients (pts). Prognosis of PCNSL is associated with several clinical and histopathological risk factors (RF). Early complete response (CR) during chemotherapy (CHT) was recently reported to be an additional independent prognostic factor in pts undergoing polychemotherapy without HDT+ASCT. In this analysis, we examined the extent to which known RF determined survival in pts who were treated with HDT-ASCT. We additionally investigated the impact of HDT-ASCT specific factors (e…

Oncologymedicine.medical_specialtyChemotherapyPerformance statusbusiness.industryProportional hazards modelmedicine.medical_treatmentImmunologyPrimary central nervous system lymphomaCell BiologyHematologyThioTEPAmedicine.diseaseBiochemistryChemotherapy regimenSurgeryTransplantationInternal medicineMedicineStem cellbusinessmedicine.drugBlood
researchProduct

Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation

2013

High-dose chemotherapy followed by autologous stem cell transplantation has been shown to be feasible and highly effective in newly diagnosed primary central nervous system lymphoma. In this retrospective multicenter study, we investigated prognosis and baseline risk factors in patients with primary central nervous system lymphoma who underwent this treatment approach. We retrospectively analyzed 105 immunocompetent patients with primary central nervous system lymphoma who underwent high-dose chemotherapy followed by autologous stem cell transplantation with or without whole brain radiotherapy as first-line consolidation treated at 12 German centers between 1997 and 2011. We estimated survi…

AdultMaleOncologymedicine.medical_specialtyLymphomamedicine.medical_treatmentAntineoplastic AgentsHematopoietic stem cell transplantationTransplantation AutologousCentral Nervous System NeoplasmsYoung AdultAutologous stem-cell transplantationRisk FactorsMedian follow-upInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineAgedRetrospective StudiesChemotherapyRadiotherapyPerformance statusbusiness.industryHematopoietic Stem Cell TransplantationPrimary central nervous system lymphomaHematologyMiddle AgedPrognosismedicine.diseaseCombined Modality TherapySurgeryTransplantationRadiation therapyTreatment OutcomeFemaleOriginal Articles and Brief ReportsbusinessHaematologica
researchProduct